Treace Medical Concepts Inc (TMCI)

NASD · Healthcare · Medical Devices · USA

Treace Medical Concepts Inc is a micro cap company (market value under $300 million) in the Medical Devices industry.

Treace Medical Concepts develops and sells surgical systems for correcting bunions and related midfoot deformities. Its primary product, the Lapiplasty 3D Bunion Correction System, combines instruments and implants to address bunion causes in three dimensions. The company markets its products to surgical podiatrists and orthopaedic foot and ankle surgeons in the United States through direct sales and independent agencies.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Treace Medical Concepts Inc stock.

Our verdict on TMCI

Overvalued: intrinsic value $0.44 per share, market price $4.44, margin of safety -910.5% (as of 2026-11-17).

Its liquidation floor, current assets minus every liability, values the shares at $0.44; the price of $4.44 is 911% above that value.

ETFs with the most weight in TMCI

6 more funds hold it; the full list is part of the paid plan.

More on TMCI

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than TMCI in Medical Devices

56 more in this industry show a wider margin of safety.

Is TMCI undervalued or overvalued?

TMCI is overvalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $0.44; the price of $4.44 is 911% above that value.

What is the intrinsic value of TMCI?

$0.44 per share (as of the 2026-11-17 close), against a market price of $4.44. That is a margin of safety of -910.5%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.